Multiscale Biofluidic and Nanobiotechnology Approaches for Treating Sepsis in Extracorporeal Circuits by Kang, Joo H.
Review Article 
 
 
 
 
 
 
 
   
BioChip J. (2020) 14(1): 63-71 
DOI 10.1007/s13206-020-4106-6  
Multiscale Biofluidic and Nanobiotechnology Approaches for 
Treating Sepsis in Extracorporeal Circuits 
 
Joo H. Kang * 
Received: 12 February, 2020 / Accepted: 1 March, 2020 / Published online: 12 March, 2020 
ⒸThe Korean BioChip Society and Springer 2020 
 
 
Abstract  Infectious diseases and their pandemics 
periodically attract public interests due to difficulty in 
treating the patients and the consequent high mortali-
ty. Sepsis caused by an imbalanced systemic inflam-
matory response to infection often leads to organ fai-
lure and death. The current therapeutic intervention 
mainly includes “the sepsis bundles,” antibiotics (an-
tibacterial, antiviral, and antifungal), intravenous flu-
ids for resuscitation, and surgery, which have signif-
icantly improved the clinical outcomes in past dec-
ades; however, the patients with fulminant sepsis are 
still in desperate need of alternative therapeutic ap-
proaches. One of the potential supportive therapies, 
extracorporeal blood treatment, has emerged and been 
developed for improving the current therapeutic effi-
cacy. Here, I overview how the treatment of infec-
tious diseases has been assisted with the extracorpo-
real adjuvant therapy and the potential utility of var-
ious nanobiotechnology and microfluidic approaches 
for developing new auxiliary therapeutic methods.   
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Introduction 
Sepsis, a systemic inflammatory disease, is caused by 
an imbalanced overwhelming systemic inflammatory 
response to infection, which often leads to organ fai-
lure and death. Because it progresses rapidly while 
the determination of a cause of infection takes hours 
to days, the current state of the art treatment of sepsis 
in hospitals requires careful assessment of patients' 
conditions, followed by proper treatment based on 
the “sepsis bundle”1. It was not until the 20th century 
that Hugo Schottmüller2 and Roger Bone3 proposed 
the modern clinical definition of sepsis. Before this 
era, sepsis was regarded as severe biological decay 
that may accompany fevers4 or a syndrome that might 
have resulted from invisible living creatures5,6.   
This new foundation for sepsis has shifted the di-
rection of the sepsis research from a source of infec-
tion to the host inflammatory response, which has led 
considerable efforts in drug development for anti- in-
flammatory therapies. Xigris, for example, a recom-
binant form of human activated protein C that has an-
ticoagulative and cytoprotective effects was devel-
oped7. After extensive clinical research that reported 
no efficacy of Xigris for treating septic patients8, Eli 
Lilly and Co. withdrew Xigris from the market9. De-
spite the lack of proper drugs that effectively mitigate 
sepsis, the mortality of sepsis has gradually reduced 
thanks to consolidated efforts of clinicians, such as 
the Surviving Sepsis Campaign Guidelines, which 
was recently updated in 20181. However, we are still 
in desperate need of developing a new strategy to 
fight against infectious outbreaks worldwide when-
ever infectious diseases, such as severe acute respir-
atory syndrome (SARS)10, Ebola11, middle east res-
piratory syndrome (MERS)12, surfaced and threat-
ened the world. In the past five years, we experienced 
multiple severe outbreaks of Ebola (2014-2016 in 
West Africa), MERS (2015 in the Republic of Korea), 
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and the recent coronavirus outbreak (COVID-19 in 
Wuhan, China). However, we mainly rely on taking 
preventative measures against epidemics due to the 
lack of proper therapeutic strategy in handling severe 
septic conditions.  
Because sepsis is a complicated and dynamic syn-
drome that involves enormous numbers of parameters 
that regulate the inflammatory network, it was chal-
lenging to inhibit a particular pathway because the 
disease can still progress by detouring the inhibited 
pathways as we have already witnessed the case of 
Xigris. Thus, some of the researchers and clinicians 
have paid attention to removing a source of infection 
that persistently triggered a catastrophic inflammato-
ry response for developing an adjuvant therapy. This 
idea was evidenced by several clinical studies sup-
porting that viral and bacterial loads in the blood are 
a major contributor to the severity and mortality of 
sepsis13,14. Due to the rapid progress of sepsis and a 
high frequency (~70%) of negative results of blood 
culture in septic human blood15, identification of a 
source of infection in time is often elusive even in 
state-of-the-art clinical settings. For this, an auxiliary 
therapeutic approach could be a preferable treatment 
option for clinicians while the conventional “sepsis- 
bundle” procedures are mitigating symptoms of se-
vere septic patients. This has led to developing sever-
al medical devices that have been available in the 
market for the past decades. This review will mainly 
scrutinize extracorporeal blood treatment approaches 
for treating sepsis and how the researchers in the in-
terdisciplinary fields of nanobiotechnology and bio-
chips could make potential contributions to improv-
ing the efficacy of the biomedical devices addressing 
the unmet needs in sepsis treatment. 
 
Pathogen-capturing Reagents Immobilized 
on Fiber Surface 
Efforts first dedicated to removing infectious reag-
ents in whole blood of septic patients were developed 
by modifying the conventional extracorporeal blood 
treatment devices, such as hemofiltration devices. The 
inner surface of the fiber bundles of the device was 
functionalized with synthetic proteins16 or antibiotics17 
that were known to capture a range of Gram-negative 
pathogens or lipopolysaccharides (LPS) (Figure 1A). 
The fibers of Toraymyxin® and oXiris®, for exam-
ple, are functionalized with polymyxin B (antibiotics) 
and polyethyleneimine (PEI) (positively charged mo-
lecule), respectively, which are known to bind Gram- 
negative bacteria and LPS (negatively charged moie-
ty). This approach has been extensively attempted in 
clinical trials as well as in large animal models be-
cause it can be simply integrated with the existing 
blood filtration devices that had already been ap-
proved for treating patients with organ failures. How-
ever, the devices based on this principle were more 
effective in depleting free LPS or pathogen debris 
probably caused by antibiotic treatment18 than re-
moving intact bacteria that were planktonic in whole 
blood. This is most likely due to the low binding effi-
ciency of relatively large bacterial cells (~ 1-2 µm in 
diameter) in comparison to submicrometer-sized LPS 
molecules. If we consider only stochastic movements 
of pathogenic materials and capturing matrix, the bind-
ing efficiency of planktonic particles in a solution to the 
capturing matrix is determined by the thermal fluctu-
ation (kd) and collisions caused by shear (kshear)19. 
Because the collision rate constant of diffusion, kd, is 
given by 
 
݇ௗ = ଶ௥೎௞್்ଷఎ௥್                 (1) 
 
where rc is the radius of a pathogen (~ 0.5 µm), and 
rb is the radius of a capturing particle, kb is the 
Boltzmann constant, T is the temperature (K), and  
is the fluid viscosity (N s m-2), the binding efficiency 
of free bacteria to a solid wall surface via thermal 
fluctuation where rb approaches an infinite radius 
becomes negligible. Thus, physical contact of bacte-
rial cells to the surface is an essential prerequisite to 
achieve the complete removal of pathogens from 
blood in this principle. 
Moreover, the efficiency of capturing LPS in blood 
should be significantly higher than whole bacteria 
because the frequency of LPS encountering the sur-
face is greater than individual intact bacterial cells 
due to their enormous numbers after being scattered 
by bactericidal antibiotics. A report published by re-
searchers at Harvard University also demonstrated 
that the use of antibiotics significantly increases the 
depletion efficiency of pathogen-associated molecu-
lar patterns (PAMPs) in a septic rodent animal mod-
el18. Thus, it is recommended to use the LPS adsorb-
ing devices, particularly along with antibiotic treat-
ment. However, in the case of infection caused by mu-
ltidrug-resistant (MDR) or pan-drug resistant (PDR) 
bacteria where the use of antibiotics is often ineffec-
tive, this approach may not be a preferable strategy. 
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Figure 1. (A) A schematic drawing of surface adsorption-based extracorporeal devices. The inner surface of fibers bundled in the 
device is functionalized with proteins or synthetic polymers, which are known to capture a wide range of pathogens and toxins in 
blood18. (B) An illustration showing a cross-sectional view of porous beads and their internal structures of the CytoSorb® filter, 
which was developed for lowering cytokine levels in blood of septic patients20. (C, D, E) Magnetic particle-assisted blood treatment 
approaches. (C) Magnetic particles are functionalized with pathogen-capturing moieties21. (D) Magnetic particles coated with an-
ti-IL6 was developed for removing a proinflammatory cytokine in blood22. (E) An engineered human FcMBL molecule conjugated 
on magnetic nanoparticles where the FcMBL molecules were designed to be oriented with carbohydrate recognition domains facing 
outward23. 
 
Porous Polymer Beads Absorbing  
Cytokines 
The severity of sepsis is often driven by overwhelm-
ing amounts of cytokines produced throughout the 
body, the cytokine storm. Cytokines are a broad cate-
gory of small proteins responsible for cell to cell sig-
naling (< 40 kDa), and their productions and surges 
in the host immune system are asynchronous. Be-
cause a variety of cytokines are responsible for the 
rapid progress of sepsis, an idea of reducing levels of 
all small molecules in septic blood was set out to de-
velop for treating septic patients. Hemofiltration (HF) 
was initially applied to lowering the concentration of 
cytokines; however, due to the relatively inefficient 
rate in depleting cytokines, the clinical trial did not 
find a significantly improved outcome for treating 
septic patients24. After a septic animal study in rats 
showed that physical adsorption of cytokines (IL-6) 
to HF filter surfaces was attributed to reducing cyto-
kine levels in blood25, the many researchers started to 
investigate how to maximize physical adsorption of 
cytokines in an extracorporeal circuit while demon-
strating their prototype devices in a small animal 
model26 and developing mathematical models pre-
dicting the cytokine removal efficiency27. The most 
well-known product based on this principle is Cyto-
Sorb® in which polymer beads with large amounts of 
the porous cavity in a range of 250 Angstroms to 
about 2000 Angstroms28 hold up small molecules, 
such as cytokines, while whole septic blood flows 
through the device (Figure 1B). However, because 
pro-inflammatory (IL-1, IL-12, IL-18, TNF-, IFN-) 
and anti-inflammatory (IL-4, IL-6, IL-10, IL-10, IL-13) 
cytokines finely orchestrate complicated molecular 
cascades of responses to infection, therapeutic strate-
gies aiming to reduce cytokine levels in blood are 
still disputable. One of the challenges in this appro-
ach is to find the right time to treat patients with ad-
sorbing filters because levels of various cytokines in 
patients are dynamic and often unpredictable29. 
 
Magnetic Nanoparticle-assisted Blood 
Cleansing Devices 
Magnetic separation is a classical isolation method 
Section 
through an 
adsorber
Hemoperfusion Adsorberbead
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structure
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C D E
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for harvesting a particular fraction of cells, molecules, 
or impurity from heterogeneous mixtures, such as 
whole blood30, various biological liquid samples31-33, 
and nanotube solutions34. This principle has been ap-
plied to reducing pathogen levels in whole blood cir-
culating in an extracorporeal circuit in vitro and in 
vivo animal models (Figure 1C-E). Advantages of the 
magnetic particles-based blood treatment methods 
over other competitors described above include that it 
offers the considerably higher collision rate constant 
of diffusion (kd, Equation (1)) and the larger active 
surface areas (Acap) capturing pathogens (kd = 10-17~ 
10-18 m3/s, Acap = ~10~102 m2/g)19,35 in comparison to 
the surface-adhesion-based bacterial capture method 
(kd0, Acap = 4~8 m2)36. It can also continuously feed 
fresh capturing reagents into the bloodstream at every 
moment instead of repassing blood through the cap-
turing surface matrix multiple times, which may 
gradually compromise the capturing ability. There are 
several parameters in magnetic blood treatment that 
determine the pathogen depletion efficiency in septic 
blood; 1) opsonin molecules that capture a broad range 
of pathogens without having to carry out prior identi-
fication of pathogens, 2) sizes and concentrations of 
magnetic particles, 3) magnetic forces exerted on the 
magnetic particle-bacteria complexes, and 4) a design 
and dimensions of microfluidic channels. Because 
there is a high degree of variety of carbohydrate chains 
or proteins expressed on bacteria, viruses, and fungi, 
it has been challenging to develop a generic opsonin 
molecule that targets a wide range of pathogens. Re-
searchers initially employed antibody molecules or 
metal chelators conjugated on magnetic particles to 
deplete a particular microorganism37,38, metal ions 
(Pb2+), drugs, and cytokines (IL-6)22 in blood (Figure 
1E). These approaches would be practical when we 
could have beforehand identified a source of infec-
tion or intoxication; however, in most infection cases, 
instantaneous identification of causative pathogens is 
a daunting task. To address this, Lee, J.-J. et al. de-
veloped synthetic ligand zinc-coordinated bis(dipi-
colylamine) (bis-Zn-DPA)-coated magnetic nanopar-
ticles, which was supposed to form bonds with ani-
onic phospholipids present on the outer surface of 
both Gram-positive and Gram-negative bacteria (Fi-
gure 2A). They also demonstrated its utility using 
Gram-negative bacteria, E. coli, bound with bis-Zn- 
DPA-coated magnetic nanoparticles39. The enginee-
red human opsonin molecule (Fc-mannose binding 
lectin, FcMBL) was also demonstrated to deplete a 
broad range of pathogens in whole blood (Figure 
2A)23. The second technical issue is how to optimize 
the size and concentrations of magnetic nanoparticles 
to maximize the efficiency of the blood cleansing 
system. Kang, J.H. et al. developed a theoretical mo-
del combining an orthokinetic collision model and a 
magnetophoretic model to predict the optimal size 
and concentrations of the magnetic nanoparticles that 
yield the most efficient depletion of pathogens in a 
buffer solution, plasma, and whole blood, respec-
tively (Figure 2B).19 Besides, the magnetic force ex-
erted on the magnetic particles and their complexes 
bound with pathogens is a determinant of magnetic 
separation, which is proportional to magnetic flux 
density gradients along the direction of magnetic pu-
lling. Although an electromagnetic system to pull out 
magnetic particles offers simplicity for switching the 
magnetic forces on and off, it appears unfavorable for 
this particular application because of the limited ma-
gnetic flux density gradients due to electromagnetic 
heating40. The permanent magnets assembled with 
alternating polarization generate the highly enhanced 
magnetic flux density gradients at a gap adjacent to 
two assembled magnets23. Recently, the Halbach ma-
gnetic array was experimentally demonstrated to ma-
nipulate magnetic nanoparticles at distances up to 18 
mm and wash magnetic particles used in a multi-
step-immunoassay process in a deep well plate41 (Fi-
gure 2C, i). The ferromagnetic microstructures also 
have been employed to augment the magnetic flux 
density gradients to manipulate superparamagnetic 
nanoparticles that exhibit relatively weak magnetic 
moments (Figure 2C, ii-iii)34,42. Finally, the demon-
stration of a new design principle for microfluidic 
channels to remove magnetic particles more effec-
tively in viscous fluids was successfully implemented 
where secondary spiral flows combined with magne-
tophoresis significantly enhanced the magnetic sepa-
ration efficiency even in undiluted whole blood in a 
continuous manner (Figure 2D) 43. Given the recent 
progress and persistent efforts dedicated to magneti-
cally removing pathogens from whole blood, the ma-
gnetic separation principle could be one day incorpo-
rated in a biomedical device from which many septic 
patients in dire need benefit in the near future. 
 
Commercial Products Available in the 
Market and Tested in Clinical Trials 
The extracorporeal biomedical devices that have ac-
quired the approval worldwide for treating septic pa-
tients predominantly base on the surface-adsorption 
principles. (Table 1) Due to their variable and incon-
clusive therapeutic efficacy, the cost covered by in-
surance supported either by government or private  
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Figure 2. Experimental parameters that determine the magnetic depletion efficiency of pathogens in blood. (A) An opsonin mole-
cule that captures a wide range of pathogens, including Gram-positive, Gram-negative, fungi, and viruses. i) zinc-coordinated 
bis(dipicolylamine) (bis-Zn-DPA) coated on magnetic particles forms coordination bonds with anionic phospholipids present on 
pathogen surfaces39. ii) An engineered human C-type lectin, mannose-binding lectin (MBL), fused to human IgG1 Fc (FcMBL) 23. 
iii) Pseudo-colored SEM images of S. aureus (upper) and E. coli (bottom) captured by magnetic nanoparticles coated with 
Fc-MBL23. (B) i) An optimal size and concentration of magnetic particles was predicted by a theoretical model combining an or-
thokinetic collision and a magnetophoretic model19. ii) The theoretical prediction (dotted line) was corroborated by the experi-
mental results (dark circles) 19. (C) The magnetic forces acting on magnetic particles can be improved by assembling permanent 
magnets with polarization angles varying clockwise by 90 (Halbach arrays)41 or ii) integrating ferromagnetic microstructures to 
enhance the magnetic flux density gradients42. iii) The nickel microstructures allows carbon nanotubes containing superparamag-
netic impurity to be selectively separated in the microfluidic channel when exposed to external magnetic fields34. (D) i) Slanted ob-
stacle arrays patterned in a microfluidic channels induce asymmetric pressure gradients across the channel44,45, which results in 
secondary lateral flows dragging the magnetic particles in spiral directions43. ii) COMSOL Multiphysics® simulation predicted the 
deflected paths of the magnetic particles, which correspond to the experimental results (iii, left panel) 43. 
 
sectors has regional differences; for instance, in the 
Republic of Korea, use of the ToraymyxinTM filters is 
not currently subsidized by general health insurance 
carriers, while in Japan, it can be reimbursed by the 
Japanese national health insurance since 199417. 
However, despite insufficient promising results of 
adjunctive extracorporeal treatment obtained by ran-
domized controlled trials (RCTs), sporadic clinical 
studies showing positive efficacy of treating septic 
patients in several cases of the clinical studies46,47 
keep the devices being used in an intensive care unit. 
One of the difficulties in pursuing RCTs of extracor-
poreal devices treating sepsis is the lack of patients 
who can be involved in the clinical trials, but this 
could be resolved when the therapeutic efficacy be-
comes notably outstanding without controversy. Be-
sides the products shown in Table 1, several startup 
companies48,49 have been striving to bring their tech-
nologies to the bedside. (Table 1) 
 
Technical and Experimental Challenges 
The most crucial role of the extracorporeal adjuvant  
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Table 1. A summary of extracorporeal devices for treating sepsis. 
 
 
therapy is to lower PAMPs levels in whole blood. 
However, despite the use of the endotoxin activity 
assay (EAATM) since 200450, there is no such a tool 
approved worldwide for measuring PAMPs levels in 
human whole blood yet at this moment. Moreover, 
recent studies reporting the sequencing results of 
pathogens in septic patient blood reveal that genome 
sequencing of pathogens in septic blood retains a 
considerable frequency of false outcomes, particular-
ly when their concentrations are low51. Because de-
pletion of PAMPs in blood in extracorporeal therapy 
varies with the effectiveness of antibiotics18, the de-
velopment of rapid diagnostic tools for antibiotic 
susceptibility test is also required52. Thus, the diag-
nostic techniques and their capability should be pree-
minently revolutionized for clinicians to achieve su-
ccessful sepsis therapy. As for the magnetic particles- 
based blood-cleansing approach, the biocompatibility 
of the particles is the priority to address the safety is-
sue in a phase I clinical trial. As the size of magnetic 
particles approaches to a nanoscale regime, the mag-
netic removal efficiency of nanoparticles turns out pro-
blematic, and their cytotoxicity becomes even more 
significant. To this end, Hermann et al. demonstrated 
that carbon-coated magnetic particles might not in-
duce toxicity in a long-term exposure study when the 
particles were delivered intravenously53. Similar ap-
proaches where magnetic particles are decorated with 
various functional materials are encouraged to pursue 
to address the unmet needs in this particular applica-
tion in the future. Rapid assessment of residual mag-
netic nanoparticles remaining in whole blood after 
blood-cleansing treatment is also critical to ensure that 
a minimal amount of the nanoparticles return to the 
patients. However, the currently available tools to qua-
ntitate the magnetic nanoparticles or measure the ma-
gnetic susceptibility of whole blood require dedicated 
equipment, such as a superconducting quantum inter-
ference device (SQUID) or a vibrating sample mag-
netometer (VSM), which are often unavailable in a 
standard research laboratory. Jang, B.H. et al. develo-
ped a microfluidic device where they can rapidly as-
sess magnetic particle concentrations in a range of 
0.01 mg/mL to 5 mg/mL by measuring the diamagnet-
ic repelling velocity of polystyrene microspheres.54 
Also, Bougas, L. et al. reported a method of detecting 
sub-picomolar magnetic nanoparticles in flowing com-
plex fluids55, which would be useful when integrated 
with the extracorporeal device to monitor low amo-
unts of the magnetic particles returning to the patients. 
While most extracorporeal blood treatment methods 
have targeted lowering endotoxin or cytokine levels 
in blood of the septic patients, extracorporeal remov-
al of viral particles has rarely been explored56. Alt-
hough the previously reported opsonin molecule, 
FcMBL23, is known to bind several virus particles, no 
data clearly demonstrating the depletion of viruses in 
human blood are available in public yet. Thus, addi-
tional efforts for proving the utility of extracorporeal 
devices decreasing viral particle concentrations in 
blood are also required to be established. 
Most in vivo animal studies have been demonstrated 
in rodent sepsis models, including cecal ligation and 
puncture (CLP) and intravenous or intraperitoneal 
infection. Before bringing the developed technology 
to clinical trials, it is essential to test the efficacy in a 
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large animal model, such as swine57, rabbit, or ba-
boon58. However, the current animal models provide 
poor predictability of human clinical outcomes58. 
Although the current sepsis animal models do not 
represent pathophysiological outcomes of human 
septic patients, fortunately, we could still utilize the 
animal models for developing the extracorporeal 
blood treatment devices. This is because we only assess 
a degree of pathogen levels depleted in the blood of 
septic animals, which may not much differ from the 
depletion efficiency in human blood, rather than stu-
dying pathophysiological or pharmacokinetic studies. 
 
Summary and Outlook 
The research resources and efforts that have been 
made for studying cancer, cardiovascular diseases, 
and other diseases have always outweighed those 
dedicated to infectious diseases. Moreover, the de-
velopment processes of conventional extracorporeal 
devices did not actively involve interdisciplinary ef-
forts in the past. As we overviewed above, there are 
many technical challenges that researchers in inter-
disciplinary fields ranging from medicine and biolo-
gy to nanotechnology, polymer sciences, and com-
plex fluid dynamics, could work together to revolu-
tionize the current extracorporeal therapeutic strate-
gies. Besides removing pathogenic materials from 
blood, elimination of activated leukocytes may have 
positive impacts on therapeutic efficacy59; however, 
more fundamental and clinical evaluations are re-
quired to follow because the detailed primary mecha-
nisms and their consequences governing sepsis pro-
gression remain largely unknown16. It is also im-
portant to note that once proving their therapeutic ef-
ficiency in RCTs, it would be worth exploring whe-
ther the extracorporeal therapeutic scenario could not 
only help decrease the mortality of septic patients but 
also improve the post-therapeutic life quality because 
about half of the survivors of sepsis suffer from the 
post-sepsis syndrome60. 
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